DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the ...
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
A study published last week presents a compact base editor that enables efficient in vivo delivery using a single adeno-associated virus (AAV) vector. The innovation, once approved in clinical trials, ...
Accelerating and de-risking late pre-clinical drug development with the zebrafish tumor xenograft (ZTX) platform. Efficacy and safety data from Ph1b, dose optimization trial of two doses of TH1902 ...
Overview The field of AAV-based gene therapy for lung diseases is evolving rapidly. Historically limited by biological barriers such as mucus and immune surveillance, lung-targeted gene delivery is ...
Collaboration with Cleveland Clinic to support creation of novel next-generation mini-gene platform to pursue monogenic diseases not addressable by conventional AAV gene therapy technologies ...
Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement Agreement leverages Taysha’s existing partnership with UT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results